LAG3 and myocarditis: In clinical trials and post-marketing data, the safety profile of relatlimab—currently the only approved LAG-3 inhibitor—does not show an increased incidence of myocarditis beyond that observed with PD-1 blockade, and no myocarditis events have been reported with other investigational LAG-3 agents [22].